Free Trial

Organigram (TSE:OGI) Hits New 52-Week High - What's Next?

Organigram logo with Medical background

Key Points

  • Organigram Holdings Inc. reached a new 52-week high of C$2.74, marking a significant increase in its share price during mid-day trading.
  • The stock is up 16.1% with a market capitalization of C$366.84 million and a PE ratio of 228.33, indicating high investor interest.
  • Organigram is a Canadian licensed producer of cannabis products, focusing on producing indoor-grown cannabis for both patients and adult recreational consumers.
  • Five stocks to consider instead of Organigram.

Organigram Holdings Inc. (TSE:OGI - Get Free Report) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as C$2.74 and last traded at C$2.74, with a volume of 833095 shares. The stock had previously closed at C$2.36.

Organigram Stock Up 16.1%

The company's 50 day simple moving average is C$2.20 and its 200-day simple moving average is C$1.87. The company has a debt-to-equity ratio of 3.07, a quick ratio of 2.62 and a current ratio of 3.36. The firm has a market capitalization of C$366.84 million, a PE ratio of 228.33, a PEG ratio of 0.42 and a beta of 2.08.

About Organigram

(Get Free Report)

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Organigram Right Now?

Before you consider Organigram, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.

While Organigram currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.